BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.30 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 2.95M

Average 4.85M

BCRX EBITDA Margin

EBITDA as a percentage of revenue.

BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 45.2%

EBITDA Margin was 45.2% in Q2 FY2026, up 27.8 pp from a year earlier. On a trailing-twelve-month basis it was -32.2%, down 43.6 pp year over year. Over 3 fiscal years it widened by 92.9 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of -56.3% for the fiscal year ending Dec 2026, down from 39.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
45.2%+492.7 pp QoQ
Last fiscal yearDec 2025
39.7%+36.9 pp YoY
LTMJun 2026
-32.2%-43.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+27.8 pp+11.7 pp-16.1 pp
1 year+36.9 pp-96.0 pp-132.9 pp
3 years+92.9 pp-9.7 pp-102.5 pp
5 years-2.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
39.7%
Year-over-year change
+36.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How BCRX compares with its peers on the latest reported figures

  • BCRX's LTM Jun 2026 EBITDA Margin of -32.2% is the highest of the 2 companies compared; the peer median is -669.6%.
  • Its year-over-year change of -43.6 pp is the lowest of 2, against a peer median of +2109.2 pp.
  • Over three fiscal years its change of +92.9 pp compares with a peer median of -668.6 pp.
BCRX Competitors Peer median
EBITDA Margin for BCRX and competitors
Company Period LTM level YoY 3-year change
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-32.2% -43.6 pp+92.9 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-669.6% +2109.2 pp-668.6 pp
PHVSPharvaris N.V.FY2025— ——
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding BCRX) -669.6%+2109.2 pp-668.6 pp

Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue157.17M270.83M331.41M450.71M874.84M
Cost of Revenue7.26M6.59M4.66M12.49M19.08M
Gross Profit149.91M264.23M326.75M438.23M855.76M
Gross Margin95.4%97.6%98.6%97.2%97.8%
Research & Development208.81M253.3M216.57M174.64M166.13M
Selling, General & Admin118.82M159.37M213.89M266.13M348.65M
Operating Expenses327.63M412.67M430.46M440.77M514.77M
Depreciation & Amortization777K1.44M1.66M1.25M1.39M
EBITDA(121.74M)(143.85M)(116.34M)12.81M347.65M
EBITDA Margin-77.5%-53.1%-35.1%2.8%39.7%
Operating Income(177.72M)(148.44M)(103.71M)(2.54M)340.99M
Operating Margin-113.1%-54.8%-31.3%-0.6%39.0%
Interest Income62K5.13M15.78M14.75M10.67M
Interest Expense59.29M99.09M108.24M98.52M78.87M
Other Income / Expenses(4.09M)(95.95M)(122.52M)(84.41M)(73.6M)
Income Before Tax(181.81M)(244.38M)(226.23M)(86.95M)267.39M
Pre-Tax Margin-115.7%-90.2%-68.3%-19.3%30.6%
Income Tax Expense2.25M2.73M310K1.93M3.53M
Net Income(184.06M)(247.12M)(226.54M)(88.88M)263.86M
Net Margin-117.1%-91.2%-68.4%-19.7%30.2%
EPS (Basic)(1.03)(1.33)(1.18)(0.43)1.26
EPS (Diluted)(1.03)(1.33)(1.18)(0.43)1.21
Weighted Avg Shares179.12M185.91M192.2M206.7M209.89M
Weighted Avg Shares (Diluted)179.12M185.91M192.2M206.7M218.58M

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Intrinsic Alpha fair value

Locked

Current Price

$7.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.